Every year, up to 3 million newborns are affected by neonatal sepsis, one of the leading causes of neonatal deaths worldwide. Shockingly, antimicrobial resistance contributes to nearly one-third of these deaths.

In this video, we explore how the Global Antibiotic Research and Development Partnership (GARDP) is addressing this urgent global health crisis. Discover our groundbreaking clinical trial aimed at validating the doses of two antibiotics for use in newborns and our mission to develop new treatments for children.